Patents Examined by Mary Maille Lyons
  • Patent number: 10669563
    Abstract: The present invention relates to methods for the production of heat shock protein complexes for use in vaccine compositions. In particular, there is provided a method for increasing the level and immunogenicity of heat shock protein complexes produced in cells by subjecting the cells to specific stress inducing stimuli. The invention further extends to the use of heat shock protein complexes produced according to the methods of the invention in the preparation of vaccine compositions for the prevention and treatment of infectious diseases and cancerous conditions.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 2, 2020
    Assignee: Immunobiology Limited
    Inventors: Camilo Colaco, Ian McEntee
  • Patent number: 10662442
    Abstract: In various aspects and embodiments, the invention relates to bacterial strains and methods for making terpene and terpenoid products. The invention provides bacterial strains with improved carbon flux through the MEP pathway, to thereby increase terpene and/or terpenoid product yield by fermentation with carbon sources such as glucose.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: May 26, 2020
    Assignee: MANUS BIO INC.
    Inventors: Ajikumar Parayil Kumaran, Chin-Giaw Lim, Souvik Ghosh, Christopher Pirie, Jason Donald, Aaron Love, Hong Nan, Hsien-Chung Tseng, Christine Nicole S. Santos, Ryan Philippe
  • Patent number: 10648045
    Abstract: Chimeric clostridial neurotoxins in which the activation loop has been replaced by an activation loop from a different subtype within the same serotype. Methods of producing, activating, and using such neurotoxins. Compositions comprising such neurotoxins. Polynucleotides, vectors and cells for expressing such neurotoxins.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: May 12, 2020
    Assignee: IPSEN BIOPHARM LIMITED
    Inventors: Daniel Kwan, David Burgin, Stephen Gavin Hackett
  • Patent number: 10646559
    Abstract: The present invention provides antigens, for use in the treatment or prevention of C. burnetii infection. Also provided are nucleic acids encoding such antigens, and antibodies raised against such antigens.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 12, 2020
    Assignee: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE
    Inventors: Julia Vipond, Kevin Bewley
  • Patent number: 10640530
    Abstract: A method is provided for facilitating extraction of a fraction from a biological sample. The biological sample includes non-desired material and a fraction-bound solid phase substrate. The method includes the steps of capturing the fraction-bound solid phase substrate and bringing an isolation buffer and the fraction-bound solid phase substrate into contact to purify the captured fraction-bound solid phase substrate.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: May 5, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: David Beebe, Lindsay Strotman, Scott M. Berry
  • Patent number: 10640537
    Abstract: The present invention provides for a system comprising (a) a first nucleic acid comprising a nucleotide sequence encoding a nucleotide sequence of interest operatively linked to a promoter comprising a repressor polypeptide binding site, and (b) a second nucleic acid comprising a nucleotide sequence encoding a repressor polypeptide having at least 70% amino acid identity with EilR, SmvR, KmrR, RcdA, or QacR; wherein expression of the nucleotide sequence of interest from the promoter is induced by the presence of a hydrophobic inducer, such as a hydrophobic cation inducer, such as a triarylmethane, acridine, phenazine, phenothiazine, or xanthene.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 5, 2020
    Assignee: The Regents of the University of California
    Inventor: Thomas L. Ruegg
  • Patent number: 10632056
    Abstract: A supplement composition formulated to support the health of a human's hair skin and nails containing biotin, Haematococcus pluvialis algae, and Reishi.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: April 28, 2020
    Assignee: The Procter & Gamble Company
    Inventors: Jennifer Marie Toomey, Paul Schulick
  • Patent number: 10610582
    Abstract: A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 7, 2020
    Assignee: PCI BIOTECH AS
    Inventors: Anders Hogset, Pal Johansen
  • Patent number: 10595530
    Abstract: Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: March 24, 2020
    Assignees: Nationwide Children's Hospital, Inc., University of Southern California
    Inventors: Steven D. Goodman, Lauren O. Bakaletz
  • Patent number: 10597665
    Abstract: A method is provided for modifying yeast to express mutant avian farnesyl disphospate synthase and the resulting modified yeast. The yeast advantageously includes additional mutants including but not limited to having ergosterol dependent growth and being erg-. The modified yeast are beneficial for the production of various terpenes including diterpenes.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: March 24, 2020
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Joe Chappell, Xun Zhuang, Shuiqin Wu
  • Patent number: 10583033
    Abstract: A method and system of reducing the likelihood of an inflammatory disease developing by providing a mucosal adhesive strip to a subject, with the strip provided with at least one of a plurality of agents effective to hinder the growth of spirochetes bacteria in a subject's oral cavity. In certain embodiments, an effective amount of Prevotella intermedia is provided to decrease the incidence of periodontitis and to reduce the progression of Alzheimer's disease. In still other embodiments, the likelihood that a subject will suffer from Alzheimer's disease is reduced by administering via local gingival application to a subject that has been diagnosed with periodontitis an effective amount of an antibiotic effective to kill spirochetes bacteria residing on the subgingival tooth area of the subject.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 10, 2020
    Inventors: Katherine Rose Kovarik, Joseph E. Kovarik
  • Patent number: 10568960
    Abstract: The invention relates to the fields of vaccines and vaccine adjuvants, and generally relates to polynucleotide adjuvants, polynucleotide vaccines and vaccine compositions. More specifically, the invention relates to said polynucleotides and vaccine compositions for use in inducing or enhancing a prophylactic or therapeutic immune response in a mammalian subject. Furthermore, it relates to said polynucleotides and vaccine compositions for use in the prophylactic or therapeutic treatment of an infectious disease, such as in the prophylactic or therapeutic treatment of leishmaniasis.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: February 25, 2020
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Pedro José Alcolea Alcolea, Ana María Alonso Ayala, Vincente Emilio Larraga Rodríguez De Vera
  • Patent number: 10570194
    Abstract: Compositions and methods of the present invention prevent, inhibit or reduce the toxic effects of proteins and toxins secreted from microbes. A method for neutralizing microbial protein products in a subject comprises administering a composition to the subject, said composition comprising plasma-derived IgM and optionally one or more excipients in a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein products.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: February 25, 2020
    Assignee: GRIFOLS WORLDWIDE OPERATIONS LIMITED
    Inventors: Thomas Barnett, David A. Ross
  • Patent number: 10555980
    Abstract: Provided herein are compositions and methods for the treatment or prevention of pathogenic infections.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: February 11, 2020
    Assignee: Vedanta Biosciences, Inc.
    Inventors: Jessica Schneider, Yun-Gi Kim, Bernat Olle, Shilpa Reddy, Jason Norman, Juan Patarroyo
  • Patent number: 10555977
    Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: February 11, 2020
    Assignee: DuPont Nutrition Biosciences ApS
    Inventors: Heli Anglenius, Kirsti Tiihonen, Nina Rautonen, Arthur Ouwehand
  • Patent number: 10533999
    Abstract: A process for stabilizing glutamate dehydrogenase (GDH) from a bacterium of the Clostridium genus, in an aqueous solution, in order to maintain the antigenic properties thereof, includes the step of mixing the glutamate dehydrogenase and a stabilizing composition which is a carboxylic acid having a carbon-based chain of at least 3 carbon atoms and comprising at least 2 —COOH groups, or a salt thereof. GDH compositions thus stabilized and a method of detecting the presence of bacteria of the Clostridium genus are also disclosed.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 14, 2020
    Assignee: BIOMERIEUX
    Inventors: Florence Bettsworth, Jérôme Martinez
  • Patent number: 10526223
    Abstract: A method for producing a microbiologic agent is described. The method includes a step of adding biomass containing a target compound-degrading microorganism and an inorganic microparticle carrier to a medium containing a target compound. The microorganisms included in the biomass are carried on the inorganic microparticles, and the medium is cultured while monitoring an abundance ratio of the target compound-degrading microorganism in microorganisms carried on the inorganic microparticle carrier. After the abundance ratio of the target compound-degrading microorganism reaches a predetermined value, the inorganic microparticle carrier carrying the target compound-degrading microorganism is collected to obtain the microbiologic agent.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: January 7, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Yosuke Nakamura, Eiji Nitta, Hiroyuki Asako, Fumiyoshi Okazaki
  • Patent number: 10502739
    Abstract: Antibiotics (Abx) are the world's most misused drugs. Antibiotics misuse occurs when the drug is administered in case of a non-bacterial infection (such as a viral infection) for which it is ineffective. Overall, it is estimated that 40-70% of the worldwide Abx courses are mis-prescribed. The financial and health consequences of Abx over-prescription include the direct cost of the drugs, as well as the indirect costs of their side effects, which are estimated at >$15 billion annually. Furthermore, over-prescription directly causes the emergence of Abx-resistant strains of bacteria, which are recognized as one of the major threats to public health today. This generates an immediate need for reliable diagnostics to assist physicians in correct Abx prescription, especially at the point-of-care (POC) where most Abx are prescribed. Accordingly, some aspects of the present invention provide methods using biomarkers for rapidly detecting the source of infection and administrating the appropriate treatment.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: December 10, 2019
    Assignee: MeMed Diagnostics Ltd.
    Inventors: Kfir Oved, Eran Eden, Ilan Ifergan
  • Patent number: 10472663
    Abstract: The present invention relates to a method for the rapid evaluation of bacterial susceptibility or non-susceptibility of bacteria to antibiotics that inhibit protein synthesis. The rationale is to identify bacterial responses that depend or are influenced by protein synthesis. If this response is prevented or reduced by the antibiotic that inhibits the protein synthesis, the bacteria are susceptible to this antibiotic. Otherwise, if the response keeps similar despite the incubation with the antibiotic, the bacteria are not susceptible or resistant to this antibiotic. These responses could be determined at the DNA lev-el, cell wall level, morphological level or any other experimental approach, including metabolic, bio-chemical, physiological or genetic processes.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: November 12, 2019
    Assignee: ABM Technologies, LLC
    Inventors: José Luis Fernández García, Jaime Gosálvez Berenguer, Germán Bou Arévalo, Maria Tamayo Novas, Rebeca Santiso Brandariz, Fátima María Otero Fariña
  • Patent number: 10463719
    Abstract: Microorganisms comprising a maltose-inducible promoter and methods of use in producing biologics and introducing biologics to sites in a maltose-dependent manner. The microorganisms include a maltose-inducible promoter operably connected to a coding sequence of a biologic. The biologic may be a polypeptide or a nucleic acid. Polypeptide biologics may include lytic proteins and/or secreted proteins. Nucleic acid biologics may include antisense RNA, other types of RNA, or other types of nucleic acids. The microorganisms can be used to produce the biologics and/or introduce the biologics to in vitro or in vivo sites in a maltose-dependent manner. The microorganisms can also be used in maltose-dependent gene silencing.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 5, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jan Peter Van Pijkeren, Jee-Hwan Oh